about
Herbal medicines for treating HIV infection and AIDSInhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agentThe use of herbal medicines in early drug development for the treatment of HIV infections and AIDSThe immunostimulatory and antimicrobial property of two herbal decoctions used in the management of HIV/AIDS in Ghana.Inhibition of HIV-1 integrase by modified oligonucleotides derived from U5' LTR.Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil.Management of chronic diarrhea in HIV-infected patients: current treatment options, challenges and future directions.In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.Low dose adrenocorticotropic hormone test and adrenal insufficiency in critically ill acquired immunodeficiency syndrome patients.Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential.Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and itsEffects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status.Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.[Evaluation of the polymorphisms in methylenetetrahydrofolate reductase gene and the levels of folate and B12 in HIV-infected patients under antiretroviral therapy].Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agentsAgents that target cysteine residues of biomolecules and their therapeutic potential
P2860
Q24246643-EEED0CCA-7182-4433-A3A2-D83C75FD5A4CQ24656023-8891AE19-516C-4C91-B360-E7368ECF6069Q28241719-FC2F5829-4A6C-428A-9454-5E2C847CCB1FQ30368408-107DB3AF-11A0-4878-8041-81F345757A8BQ31944552-FFBA47A0-5E4A-4D5A-B439-4D8678005943Q33860320-B101EDFB-42CC-494C-8B11-9212E9665F69Q33982634-1EDD9C9D-EEDD-4092-BCA1-364C0B93067FQ34112169-F66D3660-10CE-4877-AA82-7CE64030EE64Q34123716-4BA548DE-3FD1-4BA1-A001-007C6C58EE2BQ35551677-C04AE90C-8A75-4FE2-A2CB-E147071CA1A7Q35557247-E6A2BA00-0E9C-403C-A615-92A7909CE256Q35685268-BC3C23F2-C58D-4D8B-B890-A386FA940C41Q35967771-A534194A-B05D-42A1-91BF-CCBC42147C37Q36292585-6811AC3A-00B2-4BAC-B955-7760CE5617E1Q37061986-665F45E4-A893-427D-A66B-45E677BC191AQ39382195-206A28C4-71DF-4DFF-A967-4FC3CDEE7D11Q40218320-04590C05-65A8-4701-B909-D5B1BBDEFE30Q40733425-817A147D-9704-4593-9478-1210B34549EAQ40816072-06DA8C3A-9E14-4519-8DE5-04F4E8D7A11FQ43747959-D30DF8C8-0B22-440A-B568-D34F41B80F5FQ44940767-C4EFA1AB-96B3-4ADC-8506-8D6D9F409DCEQ45471093-4F28FFEE-BBCB-46F5-9A98-C025B7549F63Q46376382-A9C23A56-8B66-463B-AF5B-9990297C5941Q58863308-FB686C42-D089-4672-A2A0-2A3D565C7EB3Q58863312-5A12B71F-38D9-4C71-A74A-129C046D762B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Antiretroviral therapy: state of the HAART.
@ast
Antiretroviral therapy: state of the HAART.
@en
type
label
Antiretroviral therapy: state of the HAART.
@ast
Antiretroviral therapy: state of the HAART.
@en
prefLabel
Antiretroviral therapy: state of the HAART.
@ast
Antiretroviral therapy: state of the HAART.
@en
P1433
P1476
Antiretroviral therapy: state of the HAART.
@en
P2093
P356
10.1016/S0166-3542(99)00068-6
P577
2000-01-01T00:00:00Z